Skin Allergies: October 2006 Archives

Sun allergy drug set for phase II US trials


Sun Pharma Advanced Research Company (Sparc), the recently demerged research entity of domestic pharma major Sun Pharmaceutical, is all set to take its lead molecule for anti-allergic treatment to the phase-II trials (trials on patient) in the US.

The investigational new drug (IND) of Sparc has already received permission from the US Food and Drug Administration to enter the phase-II trials.

The phase-II trials will be conducted in the US directly by the company, using a leading local CRO (clinical research organisation). This will mark the first IND filing and phase-II studies in the US by an Indian company working independently, that’s without a partner.